Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Deffered Revenue (2023 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Deffered Revenue over the past 3 years, most recently at $4.9 million for Q4 2024.

For Q4 2024, Non-Current Deffered Revenue rose 1420.25% year-over-year to $4.9 million; the TTM value through Nov 2024 reached $4.9 million, up 1420.25%, while the annual FY2024 figure was $4.7 million, 59.97% up from the prior year.
Non-Current Deffered Revenue for Q4 2024 was $4.9 million at Lifecore Biomedical, Inc. \De\, up from $4.8 million in the prior quarter.
Over five years, Non-Current Deffered Revenue peaked at $4.9 million in Q4 2024 and troughed at $321000.0 in Q4 2023.